Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 232

1.

Potent antibody drug conjugates for cancer therapy.

Senter PD.

Curr Opin Chem Biol. 2009 Jun;13(3):235-44. doi: 10.1016/j.cbpa.2009.03.023. Epub 2009 May 4. Review.

PMID:
19414278
[PubMed - indexed for MEDLINE]
2.

In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):843-52.

PMID:
15701875
[PubMed - indexed for MEDLINE]
Free Article
3.

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD.

Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

PMID:
16417259
[PubMed - indexed for MEDLINE]
4.

Antibody-drug conjugates: targeted drug delivery for cancer.

Alley SC, Okeley NM, Senter PD.

Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17. Review.

PMID:
20643572
[PubMed - indexed for MEDLINE]
5.

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

Gerber HP.

Biochem Pharmacol. 2010 Jun 1;79(11):1544-52. doi: 10.1016/j.bcp.2010.01.015. Epub 2010 Jan 22. Review.

PMID:
20096666
[PubMed - indexed for MEDLINE]
6.

Antibody-drug conjugates in cancer therapy.

Sievers EL, Senter PD.

Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823. Epub 2012 Oct 3. Review.

PMID:
23043493
[PubMed - indexed for MEDLINE]
7.

Antibody-drug conjugates for cancer therapy.

Carter PJ, Senter PD.

Cancer J. 2008 May-Jun;14(3):154-69. doi: 10.1097/PPO.0b013e318172d704. Review.

PMID:
18536555
[PubMed - indexed for MEDLINE]
8.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
[PubMed - indexed for MEDLINE]
9.

Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.

Jeffrey SC, Nguyen MT, Moser RF, Meyer DL, Miyamoto JB, Senter PD.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2278-80. Epub 2007 Jan 27.

PMID:
17293111
[PubMed - indexed for MEDLINE]
10.

Drug-conjugated antibodies for the treatment of cancer.

Lambert JM.

Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review.

PMID:
23173552
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Contribution of linker stability to the activities of anticancer immunoconjugates.

Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD.

Bioconjug Chem. 2008 Mar;19(3):759-65. doi: 10.1021/bc7004329. Epub 2008 Mar 4.

PMID:
18314937
[PubMed - indexed for MEDLINE]
12.

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK.

Expert Opin Biol Ther. 2004 Sep;4(9):1445-52. Review.

PMID:
15335312
[PubMed - indexed for MEDLINE]
13.

The next generation of antibody-drug conjugates comes of age.

Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N.

Discov Med. 2010 Oct;10(53):329-39. Review.

PMID:
21034674
[PubMed - indexed for MEDLINE]
Free Article
14.

Photosensitizer-antibody conjugates for detection and therapy of cancer.

van Dongen GA, Visser GW, Vrouenraets MB.

Adv Drug Deliv Rev. 2004 Jan 13;56(1):31-52. Review.

PMID:
14706444
[PubMed - indexed for MEDLINE]
15.

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R.

Bioconjug Chem. 2010 Jan;21(1):84-92. doi: 10.1021/bc900315y.

PMID:
19891424
[PubMed - indexed for MEDLINE]
16.

Technology insight: cytotoxic drug immunoconjugates for cancer therapy.

Ricart AD, Tolcher AW.

Nat Clin Pract Oncol. 2007 Apr;4(4):245-55. Review.

PMID:
17392715
[PubMed - indexed for MEDLINE]
17.

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

Robak T.

Curr Cancer Drug Targets. 2008 Mar;8(2):156-71. Review.

PMID:
18336199
[PubMed - indexed for MEDLINE]
18.

Antibody-drug conjugate (ADC) clinical pipeline: a review.

Sassoon I, Blanc V.

Methods Mol Biol. 2013;1045:1-27. doi: 10.1007/978-1-62703-541-5_1. Review.

PMID:
23913138
[PubMed - indexed for MEDLINE]
19.

Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.

Prabhu S, Boswell CA, Leipold D, Khawli LA, Li D, Lu D, Theil FP, Joshi A, Lum BL.

Ther Deliv. 2011 Jun;2(6):769-91. Review.

PMID:
22822508
[PubMed - indexed for MEDLINE]
20.

Antibody conjugate therapeutics: challenges and potential.

Teicher BA, Chari RV.

Clin Cancer Res. 2011 Oct 15;17(20):6389-97. doi: 10.1158/1078-0432.CCR-11-1417.

PMID:
22003066
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk